Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: SUZUKI, HIDEKAZU, HIRASHIMA, TOMONORI, KOBAYASHI, MASASHI, OKAMOTO, NORIO, MATSUURA, YUKA, TAMIYA, MOTOHIRO, MORISHITA, NAOKO, OKAFUJI, KOHEI, SHIROYAMA, TAKAYUKI, MORIMURA, OSAMU, MORITA, SATOMU, KAWASE, ICHIRO
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2013
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915637/
https://ncbi.nlm.nih.gov/pubmed/24649195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2013.82
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados